By Stephen NakrosisKite, a Gilead company, on Friday said the U.S. Food and Drug Administration approved Yescarta to treat certain patients with lymphoma. The company said Yescarta, or axicabtagene ciloleucel, is the first CAR T-cell for "initial treatment of relapsed or refractory large B-cell lymphoma." The company also said Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival over the current standard of care. Kite said referring physicians and patients can immediately begin accessing Yescarta CAR T-cell therapy through the company's 112 authorized treatment centers in the U.S. Kite also said it had invested to expand its manufacturing capacity ahead of the FDA decision. Write to Stephen Nakrosis at stephen.nakrosis@wsj.com(END) Dow Jones Newswires04-01-22 1840ET

Source: Wall Street Journal April 02, 2022 05:02 UTC